Can Ipilimumab restore immune response in advanced NSCLC after progression on anti‐PD‐1/PD‐L1 agents?

Anti‐PD‐1/PD‐L1 agents play a crucial part in the treatment of non‐small cell cancer (NSCLC) demonstrating improved overall response rate (ORR) and overall survival (OS). Recent studies evaluating combination treatment with anti‐PD‐1 and anti‐CTLA‐4 suggests improved outcome but also increased toxic...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Thorac Cancer
Hlavní autoři: Sternschuss, Michal, Peled, Nir, Allen, Aaron M., Dudnik, Elizabeth, Rotem, Ofer, Kurman, Noga, Gal, Omer, Reches, Hiba, Zer, Alona
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley & Sons Australia, Ltd 2020
Témata:
Brief Reports
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7396365/
https://ncbi.nlm.nih.gov/pubmed/32548905
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13502
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky